Streetbeat News

Stock Prices

NTLA

Intellia Therapeutics announced positive data for its hereditary angioedema treatment, leading to a surge in its share prices.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:13 pm

CWBHF

Co-founders of Charlotte's Web Holdings, Jesse and Joel Stanley, have submitted instructions to withhold votes for four of the company's director nominees ahead of the annual general meeting on June 15, 2023. The concerned shareholders, representing 24.66% of the common shares, believe changes to the board are inevitable. Joel Stanley warns that the future of the company is at risk without urgent action.

Portfolio Pulse from Vuk Zdinjak

June 12, 2023 | 12:12 pm

RNLX

In the last quarter, 4 analysts have provided bullish ratings for Renalytix (NASDAQ:RNLX), with an average 12-month price target of $4.62, a 23.0% decrease from the previous average price target of $6.00.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:10 pm

ALV

Autoliv Inc (NYSE:ALV) reiterated its 2023 and medium and long-term outlook ahead of its investor day, maintaining its guidance for organic sales growth and adjusted operating margin. The company also plans to continue its repurchase program and has launched a new passenger airbag module.

Portfolio Pulse from Lekha Gupta

June 12, 2023 | 12:09 pm

BIIB

Biogen shares are trading lower despite the FDA's support for the company's Alzheimer's treatment, following a Friday increase in share price.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:07 pm

FN

In the last quarter, Fabrinet (NYSE:FN) received 3 bullish and 2 somewhat bullish analyst ratings. The company has an average 12-month price target of $133, representing an 8.48% decrease from the previous average of $145.33.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:07 pm

CUTR

In the last quarter, Cutera (NASDAQ:CUTR) received four somewhat bullish ratings, one indifferent rating, and one somewhat bearish rating from analysts. The average 12-month price target for the company is $35.17, with a high of $46.00 and a low of $14.00, representing a 6.58% increase from the previous average of $33.00.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:05 pm

BCOV

In the last quarter, Brightcove (NASDAQ:BCOV) received 3 bullish and 1 indifferent analyst ratings, with an average price target of $8.12, a 16% increase from the previous average of $7.00. The current price of Brightcove is $4.27.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:04 pm

CELZ

Creative Medical Technology (CELZ) has announced a $2 million stock buyback program, aiming to increase shareholder value.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 12:04 pm

ILMN

Illumina's CEO Francis deSouza has resigned amid pressure from activist investor Carl Icahn over the company's controversial $7.1 billion acquisition of cancer test maker Grail. Charles Dadswell has been named interim CEO while the board searches for a new CEO.

Portfolio Pulse from Vandana Singh

June 12, 2023 | 12:02 pm